This website uses cookies to ensure you get the best experience on our website. Learn more
Got it!ARDS (Acute Respiratory Distress Syndrome) is a severe, life-threatening medical condition characterized by widespread inflammation and fluid accumulation in the lungs. Every year, this condition kills more people than breast and prostate cancer combined. With no approved pharmacotherapy and caused by pneumonia, sepsis and trauma, this is a huge unmet medical need.
Exvastat has created the first stable formulation of imatinib, Impentri™, that can be delivered intravenously. This hugely extends its value as it can be used with patients unable to receive oral treatments due to coma. This aspect transforms our ability to prevent the tragic loss of human life due to ARDS.
Read moreOur story
Partner with us to save lives
Contact usAbout Impentri™
Impentri™ is a high impact product that is uniformly effective in a heterogeneous condition. The new treatment is based on the drug's ability to inhibit vascular leak, which drives the pulmonary oedema. It has proven effective in a number of human case reports as well as in vivo models.
ARDS currently lacks any approved pharmaceutical therapy, with treatment limited to supportive ventilatory care. As Impentri™ can significantly reduce the high mortality and incapacitating morbidities caused by ARDS, it will radically reduce the cost of care.
Read moreLatest News
Feb 21, 2022
Long-Term clinical outcome study of CounterCOVID patients published
“Lower mortality rate, better clinical status, and shorter duration of invasive ventilation were observed in hospitalised patients with COVID-19 treated with imatinib during a 90-day follow-up”
Read moreAug 06, 2021
Further investment and three new appointments announced
Exvastat Ltd (“Exvastat”) receives further investment from Cambridge Innovation Capital and announce expansion of the team with three key new appointments
Read moreJul 12, 2021
First Patients Enter Clinical Trial of Impentri for COVID-19 ARDS
The Impentri IMI2 consortium are pleased to announce the first patients have entered their clinical trial to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri™) in subjects with Acute Respiratory Distress Syndrome induced by COVID-19
Read more